Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000332

Drug Information
NameAzelastine
SynonymsAzelastinum [INN-Latin]; CID2267; L001153; 37932-96-0 (unspecified hydrochloride); DB00972; C07768; Spectrum2_000649; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; AC1L1DAR; CHEBI:2950; Azelastine (INN); Spectrum3_001984; 4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)- phthalazinone HCl; BSPBio_003584; Azelastine [INN:BAN]; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one; 1(2H)-Phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-; Azelastina; LS-109214; I14-2736; C22H24ClN3O; NCGC00177979-01; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; UNII-ZQI909440X; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; D07483; 79307-93-0 (hydrochloride); SPBio_000657; BRN 0900747; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; Azelastina [INN-Spanish]; BRD-A68888262-003-02-9; Azelastinum; azelastine; CHEMBL639; KBio3_002992; I06-0157; Optivar; 58581-89-8
Trade NameAstelin; Astepro
CompanyMeda Pharmaceuticals Inc
IndicationAllergic conjunctivitis
[ICD9: 372.14   ICD10: H10.45]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20
)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
InChIKeyMBUVEWMHONZEQD-UHFFFAOYSA-N
Canonical SMILESCN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl    
Therapeutic ClassAnti-Allergic Agents
CAS NumberCAS 58581-89-8
FormulaC22H24ClN3O
PubChem Compound IDCID 2267.
PubChem Substance IDSID 9970.
SuperDrug ATC IDR01AC03; R06AX19; S01GX07
SuperDrug CAS ID058581898;
TargetHistamine H1 receptorAntagonist[2][3]
Ref 1Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. To Reference
Ref 2Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. Epub 2008 Apr 29. To Reference
Ref 3The in vivo potency and selectivity of azelastine as an H1 histamine-receptor antagonist in human airways and skin. J Allergy Clin Immunol. 1988 Dec;82(6):1113-8. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543